NDA 214375 · Polarean
Xenoview
Xenon Xe-129 Hyperpolarized · Inhalation · Hyperpolarized Contrast Agent
NovelCDER novel approval, Dec 23, 2022: To evaluate pulmonary function and imaging
Last checked: Nov 20, 2026Latest source record: May 30, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2022
Dec 23, 2022
Approved uses
2
Original approval plus efficacy supplements
Registered trials
7
0 Phase 3, 3 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect May 30, 2025.
XENOVIEW ® , prepared from the Xenon Xe 129 Gas Blend, is indicated for use with magnetic resonance imaging (MRI) for evaluation of lung ventilation in adults and pediatric patients aged 6 years and older. Limitations of Use XENOVIEW has not been evaluated for use with lung perfusion imaging. XENOVIEW, prepared from the Xenon Xe 129 Gas Blend, is a hyperpolarized contrast agent indicated for use with magnetic resonance imaging (MRI) for evaluation of lung ventilation in adults and pediatric patients aged 6 years and older. Limitations of Use XENOVIEW has not been evaluated for use with lung perfusion imaging. ( 1 )
Mechanism: When hyperpolarized xenon Xe 129 gas is inhaled, a multi-nuclear capable MRI scanner can be used to image the hyperpolarized xenon Xe 129 distribution throughout the ventilated lung. Hyperpolarized xenon Xe 129 nuclei are directly detected by a Xe 129 MRI coil.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 30, 2025 Supplement 1 · Efficacy LetterLabel
- Dec 23, 2022 Original approval · Type 1 - New Molecular Entity NovelLabelLetterReview
1 products under this application
- XENOVIEW · XENON XE-129 HYPERPOLARIZED N/A · GAS, INHALATION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Xenon Xe-129 Hyperpolarized" as an intervention, any sponsor and status, largest first.
Mario Castro, MD, MPHAcademic, hospital or other
NCT04624490 · 260 participants (planned) · Start Nov 2, 2020 · Primary completion Oct 26, 2028
Drug: Hyperpolarized Xe129 · For: Asthma; COPD; Interstitial Lung Disease and 4 more
Sites: Kansas City, Kansas
- 129Xe MRI CardiopulmonaryRecruiting
Bastiaan DriehuysAcademic, hospital or other
NCT06038630 · 125 participants (planned) · Start Jan 12, 2024 · Primary completion Jun 30, 2028
Drug: Hyperpolarized Xe129 · For: Interstitial Lung Disease; Chronic Thromboembolic Pulmonary Hypertension; Acute Pulmonary Embolism and 3 more
Sites: Durham, North Carolina
University of Kansas Medical CenterAcademic, hospital or other
NCT04659707 · 42 participants · Start Feb 22, 2021 · Primary completion Jan 1, 2025
Drug: Hyperpolarized Xe129 · For: Covid19
Sites: Kansas City, Kansas
University of VirginiaAcademic, hospital or other
NCT02826343 · 30 participants · Start May 1, 2016 · Primary completion Jun 15, 2018
Drug: Xenon129 MRI imaging; Gadolinium MRI and 1 more · For: Pulmonary Disease, Chronic Obstructive
Sites: Charlottesville, Virginia
- Comparison of Bronchodilator Response From Three Different Aerosol Delivery Methods in Patients With COPD Using Hyperpolarized Xe 129 MRI Ventilation ImagingActive, not recruiting
Polarean, Inc.Industry
NCT06271408 · 6 participants (planned) · Start Mar 19, 2024 · Primary completion Dec 31, 2026
Drug: Albuterol Sulfate, 2.5 Mg/3 mL (0.083%) Inhalation Solution · For: Chronic Obstructive Pulmonary Disease
Sites: Charlottesville, Virginia
Bastiaan DriehuysAcademic, hospital or other
NCT06122922 · 0 participants · Start Mar 15, 2024 · Primary completion Dec 31, 2025
Drug: Hyperpolarized Xe129 · For: Pulmonary Artery Hypertension
University of Kansas Medical CenterAcademic, hospital or other
NCT04677426 · 0 participants · Start May 1, 2022 · Primary completion Aug 1, 2022
Drug: Hyperpolarized Xe129 · For: Idiopathic Pulmonary Fibrosis; Hypersensitivity Pneumonitis
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Polarean
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.